Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.1% in the 3rd quarter, Holdings Channel.com reports. The fund owned 387,356 shares of the medical research company’s stock after purchasing an additional 486 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Amgen were worth $124,810,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of AMGN. First Citizens Bank & Trust Co. grew its stake in Amgen by 5.2% in the third quarter. First Citizens Bank & Trust Co. now owns 10,054 shares of the medical research company’s stock worth $3,239,000 after purchasing an additional 497 shares in the last quarter. Blue Trust Inc. grew its position in shares of Amgen by 46.3% in the 3rd quarter. Blue Trust Inc. now owns 3,682 shares of the medical research company’s stock worth $1,150,000 after acquiring an additional 1,166 shares in the last quarter. Moss Adams Wealth Advisors LLC grew its position in shares of Amgen by 1.7% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 3,043 shares of the medical research company’s stock worth $980,000 after acquiring an additional 51 shares in the last quarter. Net Worth Advisory Group bought a new stake in shares of Amgen in the 3rd quarter valued at approximately $652,000. Finally, Precedent Wealth Partners LLC raised its position in shares of Amgen by 8.8% during the 3rd quarter. Precedent Wealth Partners LLC now owns 5,231 shares of the medical research company’s stock valued at $1,685,000 after acquiring an additional 421 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AMGN. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 target price on shares of Amgen in a research note on Thursday, September 26th. Robert W. Baird reiterated an “underperform” rating and set a $215.00 price objective on shares of Amgen in a research note on Wednesday, September 25th. Oppenheimer reissued an “outperform” rating and issued a $380.00 target price on shares of Amgen in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 price target (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Finally, Cantor Fitzgerald assumed coverage on Amgen in a report on Friday, September 27th. They issued an “overweight” rating and a $405.00 price target on the stock. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and an average price target of $329.48.

Amgen Stock Up 0.1 %

Shares of AMGN traded up $0.33 during mid-day trading on Friday, reaching $321.66. The company’s stock had a trading volume of 1,552,126 shares, compared to its average volume of 2,447,665. The company has a market cap of $172.55 billion, a price-to-earnings ratio of 45.95, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The business has a fifty day moving average of $326.07 and a 200 day moving average of $311.90. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. Amgen Inc. has a 1 year low of $249.70 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The business had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company’s revenue was up 20.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.00 earnings per share. As a group, analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.80%. Amgen’s dividend payout ratio is presently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.